Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

5440 - Different stories for different EGFR exon 19 deletion variants

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Chao Zhao

Citation

Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260

Authors

C. Zhao1, T. Jiang2, J. Li2, Y. Wang2, M. Qiao2, X. Chen3, C. Su2, C. Zhou2, X. Li4

Author affiliations

  • 1 Lung Cancer And Immunology, Shanghai Pulmonary Hospital, Tongji University, 200433 - Shanghai/CN
  • 2 Oncology, Shanghai Pulmonary Hospital, Tongji University, 200433 - Shanghai/CN
  • 3 Department Of Oncology, Shanghai Pulmonary Hospital, Tongji University, 200433 - Shanghai/CN
  • 4 Department Of Lung Cancer And Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 200433 - Shanghai/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5440

Background

Epidermal growth factor receptor (EGFR) exon 19 deletion (19del) and L858R mutation respond differently to first generation tyrosine kinase inhibitors (TKIs), however, the clinical outcomes of different 19del variants to TKIs and the resistance patterns are not well studied.

Methods

From April 2016 to August 2017, 194 treatment-naive NSCLC patients detected as EGFR exon 19 deletions using amplification-refractory mutation system were included. DNA sequencing was used to detect the subtypes. Clinicopathological features as well as patients’ outcomes to first-line EGFR TKIs were analyzed.

Results

Twelve EGFR 19del variants were confirmed in 169 of the 194 samples. Among these, p.E746_A750del was the most frequent variant (147/169, 87.0%). p.E746_A750del was more frequently found in females (p = 0.008) and never smokers (p = 0.004) than other deletions. And deletions starting with E746 was also more frequently found in these patients than L747 (p = 0.014 and p = 0.018, respectively). Interestingly, T790M occurred more frequently in p.E746_A750del than other deletions (64.3% vs 18.2%, p = 0.017) or deletions started with E746 than L747 (63.6% vs 11.1%, p = 0.012). Patients harboringdeletions starting with L747 plus insertions had significantly shorter progression-free survival (PFS) than no insertions (8.3m vs 15.0m, p = 0.008), as well as other subtypes (8.3m vs 12.8m, p = 0.016). Multivariate analysis showed that only L747 deletion plus insertions and age were independent factors influencing PFS (p = 0.015 and 0.046, respectively).

Conclusions

p.E746_A750del was the most frequent variant of EGFR exon 19del in NSCLC patients. It was more frequently found in female and never smoking patients. T790M mutation had a higher ratio in these patients when they were resistant to first-line TKI treatment. Deletions starting with L747 plus insertions had shorter PFS than other variants.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.